Please Wait
Applying Filters...
menu
    • menu
    DRL offers a portfolio of products & services, including APIs, CMO services, generics, biosimilars & differentiated formulations.

    Virtual Booth

    Contact Supplier

    Valsynthese, part of the SSE Group, is a CDMO focused on highly energetic and highly hazardous chemistry.

    Virtual Booth

    Contact Supplier

    xyz-pharma-m-2024-10-07

    Virtual Booth

    Contact Supplier

    With Fermion, start the journey of your innovative API.

    Virtual Booth

    Contact Supplier

    Bloomage is a one-stop source for CEP Sodium Hyaluronate and Hyaluronic Acid// FDA-inspected & GMP-certified.

    Virtual Booth

    Contact Supplier

    xyz-pharma-m-2024-10-07

    Virtual Booth

    Contact Supplier

    Menu

    Ensitrelvir

    ACTIVE PHARMA INGREDIENTS

    DEVELOPMENTS

    INTERMEDIATES

    DIGITAL CONTENT

    MARKET PLACE

    PharmaCompass
    Xls

    Filters

    clear-filterReset all filters
    Left Arrow
    Right Arrow

    Digital Content read-more

    Create Content with PharmaCompass, ask us

    NEWS #PharmaBuzz

    read-more
    read-more
    Japan's Shionogi says COVID treatment did not meet endpoint in late-stage trial
    Japan's Shionogi says COVID treatment did not meet endpoint in late-stage trial

    13 May 2024

    // REUTERS

    https://www.reuters.com/business/healthcare-pharmaceuticals/japans-shionogi-says-covid-treatment-did-not-meet-endpoint-late-stage-trial-2024-05-13/

    REUTERS
    13 May 2024
    Share Share
    Shionogi Presents New Ensitrelvir COVID-19 Data Supporting Effectiveness
    Shionogi Presents New Ensitrelvir COVID-19 Data Supporting Effectiveness

    11 Oct 2023

    // BUSINESSWIRE

    https://www.businesswire.com/news/home/20231010759997/en

    BUSINESSWIRE
    11 Oct 2023
    Share Share
    Shionogi Presents New Ensitrelvir Clinical and Real-World Data
    Shionogi Presents New Ensitrelvir Clinical and Real-World Data

    18 Sep 2023

    // BUSINESSWIRE

    https://www.businesswire.com/news/home/20230918485005/en

    BUSINESSWIRE
    18 Sep 2023
    Share Share
    Seven manufacturers sign sublicence agreements with MPP to produce ensitrelvir
    Seven manufacturers sign sublicence agreements with MPP to produce ensitrelvir

    27 Jun 2023

    // INDIANPHARMAPOST

    https://www.indianpharmapost.com/news/seven-manufacturers-sign-sublicence-agreements-with-the-mpp-to-produce-generic-versions-of-shionogis-covid-19-oral-antiviral-ensitrelvir-14323

    INDIANPHARMAPOST
    27 Jun 2023
    Share Share
    Shionogi to Present Data Showing COVID-19 Symptom Recurrence is Not Associated with Ensitrelvir Treatment
    Shionogi to Present Data Showing COVID-19 Symptom Recurrence is Not Associated with Ensitrelvir Treatment

    04 Apr 2023

    // BUSINESSWIRE

    https://www.businesswire.com/news/home/20230404005987/en

    BUSINESSWIRE
    04 Apr 2023
    Share Share
    Shionogi Receives U.S. FDA Fast Track Designation for Ensitrelvir Fumaric Acid
    Shionogi Receives U.S. FDA Fast Track Designation for Ensitrelvir Fumaric Acid

    04 Apr 2023

    // BUSINESSWIRE

    https://www.businesswire.com/news/home/20230403005958/en

    BUSINESSWIRE
    04 Apr 2023
    Share Share